1. Home
  2. AEF vs VYGR Comparison

AEF vs VYGR Comparison

Compare AEF & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AEF

abrdn Emerging Markets Equity Income Fund Inc.

HOLD

Current Price

$6.89

Market Cap

277.7M

Sector

Finance

ML Signal

HOLD

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$4.39

Market Cap

232.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEF
VYGR
Founded
1989
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
277.7M
232.4M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
AEF
VYGR
Price
$6.89
$4.39
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$17.00
AVG Volume (30 Days)
92.5K
474.3K
Earning Date
01-01-0001
11-10-2025
Dividend Yield
7.13%
N/A
EPS Growth
N/A
N/A
EPS
0.57
N/A
Revenue
N/A
$31,316,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$71.78
P/E Ratio
$8.86
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.40
$2.65
52 Week High
$5.53
$6.55

Technical Indicators

Market Signals
Indicator
AEF
VYGR
Relative Strength Index (RSI) 56.48 54.46
Support Level $6.67 $3.74
Resistance Level $7.11 $4.51
Average True Range (ATR) 0.10 0.21
MACD 0.03 0.06
Stochastic Oscillator 68.84 84.94

Price Performance

Historical Comparison
AEF
VYGR

About AEF abrdn Emerging Markets Equity Income Fund Inc.

ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, private equity, communication services, healthcare, real estate, and industrials.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Share on Social Networks: